RB1 and neuroendocrine carcinoma: TP53/RB1 co-alteration was significantly more common in NEC as a group and in SCNEC than in a group of matched grade 3 IDC-NST profiled by UCSF500 assay (7/45, 16%) (p < 0.001 and p = 0.001, respectively).